S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024

Catalent (CTLT) Stock Price, News & Analysis

$56.48
+0.22 (+0.39%)
(As of 03/27/2024 ET)
Today's Range
$56.14
$56.51
50-Day Range
$48.72
$59.82
52-Week Range
$31.45
$68.08
Volume
1.59 million shs
Average Volume
2.27 million shs
Market Capitalization
$10.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.46

Catalent MarketRank™ Stock Analysis

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
7.1% Downside
$52.46 Price Target
Short Interest
Healthy
4.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.63mentions of Catalent in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$21,749 Sold Last Quarter
Proj. Earnings Growth
172.92%
From $0.48 to $1.31 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.91 out of 5 stars

Medical Sector

415th out of 939 stocks

Pharmaceutical Preparations Industry

194th out of 435 stocks

CTLT stock logo

About Catalent Stock (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CTLT Stock Price History

CTLT Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
StockNews.com Begins Coverage on Catalent (NYSE:CTLT)
CTLT Apr 2024 17.500 call
CTLT Apr 2024 30.000 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Catalent slashes 90 Bay Area jobs
In-Depth Examination Of 5 Analyst Recommendations For Catalent
Catalent gains after filing 10-Q
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
3/27/2024
Next Earnings (Estimated)
6/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
17,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.46
High Stock Price Target
$63.50
Low Stock Price Target
$42.00
Potential Upside/Downside
-7.1%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
13 Analysts

Profitability

Net Income
$-256,000,000.00
Pretax Margin
-34.91%

Debt

Sales & Book Value

Annual Sales
$4.28 billion
Cash Flow
$3.25 per share
Book Value
$25.58 per share

Miscellaneous

Free Float
180,178,000
Market Cap
$10.21 billion
Optionable
Optionable
Beta
1.20
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

CTLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price target for 2024?

13 brokerages have issued 1 year price targets for Catalent's stock. Their CTLT share price targets range from $42.00 to $63.50. On average, they expect the company's share price to reach $52.46 in the next twelve months. This suggests that the stock has a possible downside of 7.1%.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2024?

Catalent's stock was trading at $44.93 at the beginning of the year. Since then, CTLT stock has increased by 25.7% and is now trading at $56.48.
View the best growth stocks for 2024 here
.

Are investors shorting Catalent?

Catalent saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 7,850,000 shares, an increase of 8.4% from the February 29th total of 7,240,000 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is presently 2.9 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings results on Friday, February, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.22. The company earned $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative trailing twelve-month return on equity of 2.43%. The business's quarterly revenue was down 10.2% compared to the same quarter last year. During the same period last year, the company posted $0.62 earnings per share.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's major shareholders?

Catalent's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.17%), Vanguard Group Inc. (11.17%), Capital World Investors (10.56%), Nomura Holdings Inc. (6.36%), Nomura Holdings Inc. (6.36%) and Price T Rowe Associates Inc. MD (4.67%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano and Thomas W Hawkeswood.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CTLT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners